EPA vs. DHA: Do These Two Omega-3s Actually Do Different Things?

You've probably heard that fish oil is good for you, but when you look at the label and see EPA and DHA listed separately, it's natural to wonder whether those numbers actually matter. Most supplement marketing treats omega-3s as interchangeable, but EPA and DHA are structurally different molecules that do different things once they're inside your body.

Whether EPA or DHA is more relevant to your health goals depends on what you're trying to address and where your baseline levels sit. Superpower's baseline panel includes testing that reflects your omega-3 status alongside the inflammatory and metabolic markers that determine how well you're using what you're taking.

Key Takeaways

• EPA and DHA are both omega-3 fatty acids, but they have distinct structural and functional roles in the body.
• EPA is more anti-inflammatory and appears more effective for mood disorders like depression.
• DHA is the dominant structural fat in the brain and retina, critical for cognitive and visual function.
• Clinical trials show EPA at doses above 60% of total EPA+DHA is more effective for depression than balanced formulas.
• The omega-3 index measures EPA+DHA in red blood cells and reflects long-term tissue status better than serum tests.
• Cardiovascular benefits appear with both EPA and DHA, but high-dose EPA trials show stronger effects on major cardiac events.
• Choosing the right ratio depends on your goal: higher EPA for inflammation and mood, higher DHA for brain structure and cognition.

What EPA and DHA Actually Are, and Why Structure Matters

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are both long-chain omega-3 polyunsaturated fatty acids, meaning they have multiple double bonds in their carbon chains. EPA has 20 carbons and 5 double bonds; DHA has 22 carbons and 6 double bonds. That two-carbon difference changes how each molecule behaves in cell membranes and what the body can do with it.

EPA is a precursor to signaling molecules called eicosanoids, which regulate inflammation, immune response, and platelet aggregation. When EPA is incorporated into cell membranes, it competes with arachidonic acid (an omega-6 fatty acid) for the same enzymes, shifting the balance away from pro-inflammatory signaling. This competition mechanism explains why EPA has potent anti-inflammatory effects that show up in markers like high-sensitivity C-reactive protein and inflammatory cytokines.

DHA, by contrast, is less involved in acute inflammatory signaling and more involved in structural roles. It's the most abundant omega-3 in the brain, making up roughly 40% of the polyunsaturated fatty acids in neuronal membranes, and about 60% of the fatty acids in the retina. DHA's extra length and flexibility allow it to influence membrane fluidity, receptor function, and synaptic plasticity. It's also a precursor to specialized pro-resolving mediators like resolvins and protectins, which help resolve inflammation after the acute phase rather than simply blocking it.

The body can convert a small amount of EPA to DHA, but the conversion rate is inefficient, typically less than 10%. This means that if you're supplementing with EPA alone, you're not reliably raising DHA levels, and vice versa. The ratio you consume matters because the two molecules don't substitute for each other in function.

What the Clinical Trials Show for Mood and Depression

The most consistent evidence for differential effects between EPA and DHA comes from depression research. A 2011 meta-analysis published in the Journal of Clinical Psychiatry found that EPA was significantly more effective than DHA in reducing depressive symptoms, and that formulas with EPA comprising at least 60% of total EPA+DHA showed the strongest effects. Trials using balanced or DHA-dominant formulas showed weaker or null results.

One well-designed trial compared pure EPA (1 gram per day) to pure DHA (1 gram per day) in patients with major depressive disorder. EPA significantly reduced depression scores; DHA did not. Some research suggests that combining EPA and DHA at equal ratios may yield different mood-related outcomes than EPA-dominant formulations, possibly due to competitive incorporation into cell membranesut providing the same benefit in this context.

The mechanism appears to be EPA's ability to modulate neuroinflammation and influence serotonin and dopamine signaling. Elevated inflammatory markers, particularly high-sensitivity C-reactive protein and interleukin-6, are common in depression, and EPA reduces both. DHA, while critical for brain structure, does not appear to have the same acute anti-inflammatory effect that drives mood improvement in clinical populations.

This does not mean DHA is irrelevant to mental health. Long-term cognitive function, neuroprotection, and brain development all depend heavily on DHA. But for acute mood disorders, particularly depression with an inflammatory component, EPA is the more pharmacologically active molecule.

How DHA Supports Brain Structure, Cognition, and Vision

DHA is the most abundant fatty acid in the gray matter of the brain and in the photoreceptor cells of the retina. It's incorporated into phospholipids in neuronal membranes, where it influences membrane fluidity, receptor density, and the function of ion channels. This structural role is why DHA is critical during fetal and early childhood development, when the brain is rapidly building new tissue.

In adults, DHA status correlates with cognitive performance, particularly in tasks involving memory, processing speed, and executive function. Observational studies consistently show that higher DHA levels in red blood cells (measured as part of the omega-3 index) are associated with larger hippocampal volume and better cognitive aging (2024 meta-analysis). Supplementation trials in older adults with mild cognitive impairment have shown that DHA, either alone or combined with EPA, improves memory function, though the effect size is modest and most pronounced in individuals with low baseline levels.

DHA is also the precursor to neuroprotectin D1, a lipid mediator that protects neurons from oxidative stress and promotes cell survival after injury. This is one reason DHA supplementation is being studied in neurodegenerative diseases like Alzheimer's, though results have been mixed, likely because intervention occurs too late in the disease process to reverse structural damage.

In the retina, DHA makes up more than half of the fatty acids in the outer segments of photoreceptor cells. It's essential for the function of rhodopsin, the light-sensitive protein that initiates the visual signal. DHA is a major structural component of retinal tissue, and adequate DHA status during development is considered important for visual maturation. In adults, higher DHA intake is associated with a reduced risk of age-related macular degeneration, though the evidence for therapeutic benefit after diagnosis is less clear (2024 meta-analysis).

Cardiovascular Effects: Where EPA and DHA Overlap and Diverge

Both EPA and DHA reduce triglycerides, improve endothelial function, and modulate platelet aggregation, but the magnitude and mechanisms differ. High-dose EPA (4 grams per day of purified icosapent ethyl) has been shown in large randomized controlled trials to reduce major adverse cardiovascular events, including heart attack and stroke, in patients with elevated triglycerides on statin therapy (2020 meta-analysis). The REDUCE-IT trial, published in the New England Journal of Medicine, found a 25% relative risk reduction in cardiovascular events with EPA supplementation.

DHA, by contrast, has not shown the same level of benefit in cardiovascular outcome trials. Some research has observed differential effects of EPA and DHA on LDL cholesterol, with EPA appearing to have a more neutral or favorable profile. DHA does increase HDL particle size and number, which is generally considered favorable, but the net effect on cardiovascular risk appears smaller than with EPA.

The difference may come down to EPA's more potent anti-inflammatory and antiplatelet effects:

• EPA reduces the production of thromboxane A2, a molecule that promotes platelet clumping and vasoconstriction, more effectively than DHA.
• EPA lowers levels of inflammatory markers like high-sensitivity C-reactive protein and interleukin-6, which are independent predictors of cardiovascular events.
• DHA improves arterial compliance, reduces blood pressure slightly, and supports autonomic nervous system function, which influences heart rate variability.

The optimal approach for cardiovascular health likely involves both EPA and DHA, but if forced to choose, the evidence tilts toward EPA for secondary prevention in high-risk populations.

How Much to Take, Which Form, and When

Dose

For general health and maintenance, a combined EPA+DHA dose of 1 to 2 grams per day is supported by most guidelines. For therapeutic use in depression, trials have used 1 to 2 grams of EPA per day, with formulas containing at least 60% EPA relative to total EPA+DHA. For cardiovascular risk reduction, the REDUCE-IT trial used 4 grams per day of purified EPA. For cognitive support, trials have used 1 gram of DHA per day, often combined with 200 to 400 milligrams of EPA. The upper tolerable limit for combined EPA+DHA is generally considered to be 5 grams per day, though doses above 3 grams should be discussed with a physician, particularly if you're on anticoagulant or antiplatelet medications, as omega-3s can increase bleeding risk at high doses.

Form

Omega-3s are available as triglycerides, ethyl esters, phospholipids, and re-esterified triglycerides. Triglyceride and phospholipid forms are absorbed more efficiently than ethyl esters, particularly when taken without food. If you're using an ethyl ester form, take it with a meal containing fat to improve absorption. Re-esterified triglycerides offer a middle ground: better absorption than ethyl esters, but not as expensive as phospholipid forms. Prescription omega-3 products (icosapent ethyl, omega-3 acid ethyl esters) are pharmaceutical-grade and standardized, which matters for high-dose therapeutic use. Over-the-counter supplements vary widely in purity, oxidation status, and actual EPA/DHA content, so third-party testing (USP, IFOS, or NSF certification) is worth checking.

Timing

Omega-3s are fat-soluble, so taking them with a meal that contains fat improves absorption. There's no strong evidence that time of day matters, though some people report fewer gastrointestinal side effects (fishy burps, nausea) when taking omega-3s with dinner rather than breakfast. Splitting the dose (e.g., 1 gram in the morning, 1 gram in the evening) can also reduce GI discomfort.

Ratio

If your goal is reducing inflammation or improving mood, prioritize EPA. A 2:1 or 3:1 EPA:DHA ratio is common in formulas designed for these purposes. If your goal is cognitive support, brain health, or vision, prioritize DHA. A 1:2 or 1:3 EPA:DHA ratio is more appropriate. For general cardiovascular and metabolic health, a balanced 1:1 ratio or slight EPA dominance is reasonable.

Who Benefits Most from EPA, and Who Needs More DHA

EPA is most beneficial for individuals with elevated inflammatory markers, mood disorders (particularly depression with an inflammatory component), or cardiovascular risk. If your high-sensitivity C-reactive protein is above 2 mg/L, or if you have a history of depression, anxiety, or cardiovascular disease, an EPA-dominant formula is a reasonable choice.

DHA is most beneficial for individuals focused on cognitive performance, neuroprotection, or visual health. Pregnant and breastfeeding women have higher DHA requirements because fetal and infant brain development depends heavily on maternal DHA supply. Older adults concerned with cognitive aging, and individuals with a family history of neurodegenerative disease, may also benefit from higher DHA intake.

Vegetarians and vegans are at higher risk of low EPA and DHA status because plant-based omega-3s (alpha-linolenic acid from flaxseed, chia, walnuts) convert poorly to EPA and DHA. Algal oil supplements, which provide DHA and sometimes EPA, are the most direct plant-based source. Genetic variation in the FADS1 and FADS2 genes, which encode enzymes involved in omega-3 metabolism, also influences how efficiently you convert and utilize EPA and DHA, though direct testing of omega-3 status is more actionable than genetic testing in this context.

Individuals on anticoagulant or antiplatelet medications (warfarin, clopidogrel, aspirin) should use caution with high-dose omega-3s, as they can increase bleeding risk. Those with fish or shellfish allergies should confirm that their supplement is molecularly distilled and free of protein contaminants, or use algal oil instead.

Testing Your Omega-3 Status: What the Omega-3 Index Actually Tells You

The omega-3 index is the percentage of EPA+DHA in red blood cell membranes, expressed as a percentage of total fatty acids. It reflects long-term omega-3 status (over the past 2 to 3 months) and correlates with tissue levels in the brain, heart, and other organs far better than serum or plasma omega-3 measurements, which fluctuate with recent intake.

An omega-3 index below 4% is considered high risk for cardiovascular disease. An index between 4% and 8% is intermediate risk. An index above 8% is considered cardioprotective and optimal for most health outcomes. Most Americans have an omega-3 index between 4% and 5%, well below the target range.

Testing your omega-3 index before supplementing gives you a baseline. Testing again after 3 to 4 months of supplementation tells you whether your dose and form are actually raising your levels. Some people are poor absorbers or rapid metabolizers and need higher doses to reach target levels. Others reach optimal levels with modest intake.

The omega-3 index also provides context for interpreting other biomarkers. For example, if your high-sensitivity C-reactive protein is elevated and your omega-3 index is low, increasing EPA intake is a mechanistically sound intervention. If your omega-3 index is already above 8% and inflammation is still high, the problem lies elsewhere.

Other relevant markers to track alongside omega-3 status include triglycerides, apolipoprotein B, fasting insulin, and inflammatory markers like high-sensitivity C-reactive protein. Omega-3s influence all of these, and seeing the full picture helps you understand whether supplementation is moving the needle on the outcomes you care about.

Getting a Real Picture of Your Omega-3 Status

Most people supplementing omega-3s are doing so without knowing where their levels actually sit or whether the dose and ratio they've chosen are appropriate for their biology. The omega-3 index is the most reliable way to assess long-term EPA and DHA status, but it's rarely included in standard blood panels. Superpower's 100+ biomarker panel includes the markers that tell you whether your omega-3 intake is translating into the metabolic, inflammatory, and cardiovascular changes you're aiming for. Seeing your omega-3 status alongside triglycerides, inflammatory markers, and insulin sensitivity gives you a complete picture of whether your supplementation strategy is working or whether you need to adjust dose, ratio, or form.